Agios Pharmaceuticals, Inc. (AGIO) EPS Estimated At $-1.62

July 14, 2018 - By Kristen Paramore

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.72 in Q1 2018. Its up 0.50, from 1.22 in 2017Q4. It increased, as 13 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.93 million shares or 15.82% more from 45.70 million shares in 2017Q4 were reported.
Partner Management Limited Partnership invested in 0.69% or 7,821 shares. Btg Pactual Global Asset Mgmt Ltd owns 7,979 shares for 0.18% of their portfolio. Gam Ag reported 24,200 shares stake. Moreover, Envestnet Asset Mngmt Inc has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Lord Abbett And Ltd Llc reported 1.04 million shares. 24,478 are held by Legal & General Grp Public Ltd Co. Tarbox Family Office owns 16 shares for 0% of their portfolio. Oppenheimer & accumulated 0.04% or 19,437 shares. United Service Automobile Association reported 7,342 shares. American Intll Grp Incorporated accumulated 0% or 1,120 shares. Pictet Asset Mgmt Ltd has invested 0.06% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Point72 Asia (Hong Kong) Limited, Hong Kong-based fund reported 453 shares. Fernwood Investment Ltd Llc reported 25,150 shares. Point72 Asset Mngmt L P holds 406,090 shares or 0.14% of its portfolio. Savings Bank Of Montreal Can stated it has 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Since January 16, 2018, it had 1 insider buy, and 32 selling transactions for $31.33 million activity. The insider Biller Scott sold 3,000 shares worth $228,128. Hoerter Steven L. also sold $1.87M worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Tuesday, January 23. Foster-Cheek Kaye I sold $557,396 worth of stock. 2,000 shares were sold by Bowden Christopher, worth $185,786 on Tuesday, June 12. Scadden David also bought $16,688 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Friday, March 16. Alenson Carman sold $23,104 worth of stock or 272 shares.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.62 EPS on August, 14.They anticipate $0.16 EPS change or 8.99 % from last quarter’s $-1.78 EPS. After having $-1.63 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -0.61 % EPS growth. The stock decreased 0.09% or $0.08 during the last trading session, reaching $90.4. About 158,829 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 88.28% since July 14, 2017 and is uptrending. It has outperformed by 75.71% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 7 analysts covering Agios Pharma (NASDAQ:AGIO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Agios Pharma had 8 analyst reports since February 14, 2018 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Outperform” rating by Credit Suisse on Wednesday, April 11. The firm has “Buy” rating by Piper Jaffray given on Wednesday, May 30. Credit Suisse maintained it with “Buy” rating and $80.0 target in Thursday, February 15 report. JP Morgan maintained the stock with “Overweight” rating in Thursday, February 15 report. Oppenheimer initiated the stock with “Hold” rating in Monday, June 18 report. The stock has “Buy” rating by RBC Capital Markets on Wednesday, February 14.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.21 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals …” on June 29, 2018, also Nasdaq.com with their article: “Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and …” published on June 26, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Nasdaq.com and their article: “Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency …” published on June 18, 2018 as well as Seekingalpha.com‘s news article titled: “Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal” with publication date: July 01, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.